Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HB002 M

Next Previous
X
Search
Drug Profile

HB002 M

Alternative Names: HB-002-1M; HB-002.1; HB-002.1M; Recombinant human vascular endothelial growth factor receptor-immunoglobulin Fc fusion protein

Latest Information Update: 08 Apr 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Huabo Biopharm
  • Class Antineoplastics; Eye disorder therapies; Immunoglobulins; Recombinant fusion proteins
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 08 Apr 2022 Phase-II clinical trials in Diabetic macular oedema in China (Intravitreous)
  • 08 Apr 2022 Phase-II clinical trials in Wet age-related macular degeneration (In the elderly, In adults) in China (Intravitreous)
  • 25 Nov 2021 HB002 M is still in phase-I development in Wet age-related macular degeneration(In the elderly, In adults) in China (Intravitreous, Injection) (Huabo Biopharm, November 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top